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Abstract
Objective: Self-perception of changes in body fat among HIV+ persons is
associated with decreased health related quality of life in cross-sectional studies.
The longitudinal impact of body fat changes on health related quality of life, while
accounting for comorbidity and anatomic location or severity of body fat changes, is
unknown.
Design: This was a longitudinal analysis of HIV+ and HIV- Multicenter AIDS Cohort
Study (MACS) participants who completed questionnaires assessing self-perceived
body fat changes (baseline visit) and a health related quality of life (Short Form-36)
at baseline and then >5 years later.
Methods: Relationships between body fat changes and change in Short Form-36
Physical and Mental Component Summary scores were investigated using mixed-
model regression.
Results:We studied 270 HIV+ and 247 HIV- men. At baseline, >50% of HIV+ men
reported body fat changes; physical component but not mental component
summary scores were lower among HIV+ men who reported moderate/severe leg
or abdominal fat changes (p,0.05). At follow-up, physical component summary
OPEN ACCESS
Citation: Erlandson KM, Reynolds SM, Cox C,
Palella FJ, Witt MD, et al. (2014) Self-Reported
Body Fat Change in HIV-Infected Men Is a Marker
of Decline in Physical Health-Related Quality of
Life with Aging, Independent of Co-Morbidity. PLoS
ONE 9(12): e114166. doi:10.1371/journal.pone.
0114166
Editor: Philip Anglewicz, Tulane University School
of Public Health, United States of America
Received: August 19, 2014
Accepted: November 5, 2014
Published: December 1, 2014
Copyright:  2014 Erlandson et al. This is an
open-access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and repro-
duction in any medium, provided the original author
and source are credited.
Data Availability: The authors confirm that, for
approved reasons, some access restrictions apply
to the data underlying the findings. The MACS
Study data is maintained by the Center for the
Analysis of MACS Data (CAMACS). A de-
identified, freely available public dataset is avail-
able at http://www.statepi.jhsph.edu/macs/pdt.html.
To protect confidentiality of the MACS participants,
this data is highly de-identified and does not
contain all variables used for the current analysis.
For example, data in the public dataset may be
grouped into categories rather than continuous
variables, and dates are changed to years.
Individuals interested in obtaining additional data
should submit a data request to Lisa Jacobson
(ljacobs1@jhu.edu).
Funding: The Multicenter AIDS Cohort Study
(MACS) is supported through the following grants
from the National Institutes of Health, National
Institute of Allergy and Infectious Diseases (NIAID),
with additional supplemental funding from the
National Cancer Institute (NCI): UO1-AI-35042,
UL1-RR025005, UO1-AI-35043, UO1-AI-35039,
UO1-AI-35040, UO1-AI-35041, UL1TR000124.
This does not alter the authors’ adherence to
PLOS ONE policies on sharing data and materials.
KME received funding from the National Institutes
of Health, National Institute on Aging
(R03AG040594), and the John A. Hartford
Foundation, Centers of Excellence in Aging (http://
www.jhartfound.org/). The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: TTB serves on the board
PLOS ONE | DOI:10.1371/journal.pone.0114166 December 1, 2014 1 / 15
scores were significantly lower among men with face, leg, or abdominal fat changes
compared to men without perceived fat changes (p,0.05). No significant changes
were seen in mental component scores by fat change location or severity. In the
final model, body fat changes at any site or severity were significant predictors of a
decline in physical component summary score (p,0.05), independent of
demographics or comorbidities. Mental component summary score was not
associated with body fat changes, but higher mental component summary score
was associated with increasing age and time.
Conclusions: Negative self-perceived body fat changes were associated with
decline in physical health related quality of life, independent of comorbidities, and
may be a marker of an increased risk for physical function decline with aging.
Introduction
Abnormalities in body fat distribution among HIV-infected (HIV+) persons,
including central lipohypertrophy and peripheral subcutaneous lipoatrophy, were
recognized soon after the introduction of highly active antiretroviral therapy
(HAART) [1]. While initially these abnormalities were thought to represent a
single entity that was referred to as lipodystrophy, most data suggest that
lipohypertrophy and lipoatrophy are distinct entities with separate etiologies and
risk factors, although coexistence in an individual patient is common [2–4]. Both
of these disorders are also independently associated with adverse metabolic
consequences including dyslipidemia, insulin resistance, metabolic syndrome, and
with increased levels of systemic inflammation or immune activation, all of which
may increase the risk of cardiovascular disease, diabetes, and mortality [5–9].
In addition to the metabolic and inflammatory consequences, body fat changes
are stigmatizing, and may impact the way in which HIV+ persons perceive their
overall health and self-esteem. Persons affected by lipoatrophy or lipohypertrophy
were more than twice as likely to feel that their body fat changes were noticed by
others compared to persons without body fat changes [10,11]. These negative
perceptions can impact antiretroviral adherence and quality of life, as shown in
prior studies [10,12–16]. In one study, two-thirds of HIV+ participants reported
that they would be willing to trade a year of life not to have ‘‘lipodystrophy’’ [17].
Many of the studies exploring the impact of perception of body fat changes on
health-related quality of life (HR-QoL) measures have been small; few have
differentiated between the effects or severity of lipoatrophy or lipohypertrophy
[14,15,18,19], few have included HIV-uninfected (HIV-) controls [20], and none
have adjusted for other comorbid illnesses common with aging that may also
impact HR-QoL. Furthermore, only one published study was longitudinal, and
was limited to 37 men with lipoatrophy, lipohypertrophy or both, and had only
two years of follow-up [20].
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Although the incidence of HIV-associated lipoatrophy has decreased with
earlier initiation of more modern, less toxic ART [21], the impact of self-perceived
body fat changes on the HR-QoL among persons aging with HIV is not well
understood. The goal of the present study was to determine the association
between the presence and severity of self-perceived body fat changes in the face,
leg or abdomen with physical and mental HR-QoL among HIV+ persons
receiving HAART compared to HIV- persons.
Methods
Study Population
The Multicenter AIDS Cohort Study (MACS) is an ongoing multicenter
prospective cohort study of the natural and treated histories of HIV infection
among homosexual and bisexual men in the United States who are followed on a
semi-annual basis. The study design has been described previously [22,23]. Each
semi-annual MACS study visit includes a comprehensive physical examination,
blood specimen collection for CD4 cell count and plasma HIV-1 RNA
determination, and an interviewer-administered questionnaire which provides
data on demographics, disease characteristics, and specific HIV antiretroviral
medication use. Additionally the HR-QoL Medical Outcomes Study Short Form-
36 Health Survey (SF-36), the most widely used and best validated instrument of
HR-QoL [24], is self-administered at each study visit. The institutional review
boards at each site approved study protocols and forms, with approval by the
Johns Hopkins University for the Center for the Analysis and Management of the
Data from the Multicenter AIDS Cohort Study (CAMACS), IRB No:
H.34.99.07.12.A.Each participant provided written informed consent.
HIV+ and HIV- participants who attended study visit 31 (April-October 1999),
were considered for study inclusion. At this visit, both HIV+ and HIV- men were
asked about the self-perception of body fat changes in the face (loss), legs (loss),
and abdomen (gain) in the previous 2 years (‘‘In the past 2 years, have you
noticed any changes in the distribution or in the amount of your body fat [either
loss or gain]?’’), and were asked to assess the severity of the body fat changes at
each anatomic site (‘‘If ‘yes’, which parts of your body were affected and how
severely?’’). At each subsequent semi-annual visit, men were then asked whether
perceived fat changes at these sites had been noted in the previous 6 months and if
so, to rate the current severity. Men were categorized into one of the following
categories of self-perceived body fat changes based on their response to the visit 31
questionnaire: ‘‘None’’, ‘‘Mild’’, ‘‘Moderate/Severe’’. The visit 31 response was
carried forward to subsequent semi-annual visits unless the participant reported a
change at which point their response was updated.
To ensure that HIV+ men had been HAART-exposed at the time of the
assessment of self-perceived body fat changes, we used responses provided at a
semi-annual assessment 5 (+/21) years after HAART initiation with concurrently
existing SF-36 data. This visit was defined as the baseline visit. HAART was
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defined based on the Department of Health and Human Services guidelines as use
of three or more antiretroviral medications from at least two classes including: a
protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, a nucleoside
reverse transcriptase inhibitor, an integrase inhibitor, or an entry inhibitor [25].
Outcome Measures
The HR-QoL data from the SF-36 can be summarized using a composite measure
of physical and mental health. The physical health component score (PCS)
summarizes 4 scales critical to physical HR-QoL: Physical Functioning, Role-
Physical, Bodily Pain, and General Health. The mental health component score
(MCS) summarizes 4 scales critical to mental HR-QoL: Vitality, Role-Emotional,
Social Functioning, and Mental Health. Scores are normalized to a population
mean of 50 with a standard deviation of 10 [26]. To examine the longitudinal
change in HR-QoL, a follow-up visit was defined as the most recent visit at which
the SF-36 was completed, and at least 5 years after the baseline visit (median
duration 7.5 years), Figure 1.
Independent Variables
HIV control was assessed by determining the proportion of post-HAART visits
prior to the baseline or follow-up visits with plasma HIV-1 RNA ,400 copies/ml.
Hepatitis C virus (HCV) infection was defined as a detectable hepatitis C virus
RNA level in serum; all others were considered uninfected with HCV. The
comorbidity score was defined as the total number of the following comorbid
conditions: 1) depression (Centers for Epidemiologic Studies Depression Scale
score greater than 16 [27]), 2) hypertension (systolic blood pressure greater than
140 mmHg or diastolic pressure greater than 90 mmHg), 3) diabetes mellitus
(fasting glucose greater than or equal to 126 mg/dL, or self-report of a clinical
diagnosis with use of medication), 4) Dyslipidemia (either fasting total cholesterol
greater than or equal to 200 mg/dL, low-density lipoprotein greater than or equal
to 130 mg/dL, high-density lipoprotein less than 40 mg/dL, triglycerides more
than or equal to 150 mg/dL, or use of lipid-lowering medications with self-report
of a clinical diagnosis 5) kidney disease (estimated glomerular filtration rate less
than 60 mL/min/1.73 m2 using the Modification of Diet in Renal Disease
equation [28] or a urine protein-to-creatinine ratio greater than or equal to
200 mg protein/1 g creatinine), 6) liver disease (alanine transaminase or aspartate
aminotransferase .150 IU/L), 7) cancer within 1 year (diagnosis at or within a
year of the relevant visit [29]).
Statistical Analysis
Mixed-model regression analysis of the HIV+ participants was performed to
investigate the relationship between the severity of self-reported body fat changes
(none versus mild versus moderate/severe) at the baseline visit and the PCS and
MCS at the baseline and follow-up visits. The mixed model also included a time
Body Fat Changes and Quality of Life with Aging
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effect to assess the difference between the two time points, as well as the
interaction between self-reported body fat changes and time. To examine specific
differences among the 3 anatomic locations62 time points 56 groups, we made
comparisons between pairs of adjusted means. Modeling was performed
separately for the face, legs, and abdomen. All models were adjusted for age, race
(Non-white versus White), education (college or more versus no college), HAART
use at the time of the visit, co-morbidity score, and proportion of previous post-
HAART visits with plasma HIV RNA (viral load) ,400 copies/mL. For
comparison we ran a similar analysis on the HIV- subgroup, adjusting for age,
race, education, and comorbidities.
In a second analysis, we first used mixed models to determine the difference in
PCS and MCS by HIV serostatus and evaluated whether the effect of HIV
serostatus status differed over time. We then added the self-reported body fat
change variable to the above model to determine whether the severity of body fat
changes was related to physical and mental health-related quality of life and
whether inclusion of this variable altered the effect of HIV serostatus. In a third
model, we then added the co-morbidity score to the model to determine whether
any of the effect related to HIV serostatus or body fat change was due to the
burden of co-morbid conditions. All analyses were done using SAS (9.2).
Results
As shown in Figure 2, the analytic sample included 270 HIV+ and 247 HIV- men
with non-missing data out of 1064 (672 HV+ and 392 HIV- men) who attended
the baseline visit. The median time to the follow-up visit was 12.1 years after
HAART initiation (IQR: 11.2, 12.7 years) and 7.5 years after the baseline visit
(IQR: 6.9. 7.7).
Table 1 shows the participant characteristics at the baseline and follow-up visit.
HIV+ men were slightly younger and had a lower body mass index than the HIV-
men. Most of the men were white and most were college educated. The median
number of comorbid conditions at the baseline visit was one for both the HIV+
Figure 1. Study design indicating the relationship between the time highly active antiretroviral therapy
(HAART) was initiated, the baseline visit where the initial Short Form (SF)-36 health related quality of
life (HR-QoL) questionnaire was completed, and the follow-up visit when the second questionnaire
was completed.
doi:10.1371/journal.pone.0114166.g001
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and HIV- men, with the most prevalent conditions being dyslipidemia,
depression, hypertension, and diabetes mellitus. The prevalence of diabetes
mellitus, hypertension, dyslipidemia, and kidney disease increased over the
follow-up interval for both HIV+ and HIV- men.
Among the HIV+ men, the baseline median CD4 cell count was 544 cells/uL
and HIV-1 RNA levels was undetectable at 80% of the visits since HAART
initiation. At the follow-up visit, the median CD4 cell count was 557 cells/uL and
HIV-1 RNA levels were undetectable at 92% of visits since HAART initiation. The
use of stavudine, zidovudine, and protease inhibitors declined between the
baseline and the follow-up visit.
Self-perceived fat changes at baseline were significantly different between HIV+
and HIV- men in the face (p,0.001), legs (p,0.001), and abdomen (p50.033).
Over 50% of HIV+ men and less than 10% of HIV- men reported body fat
changes in the face or legs. Sixty-three percent of HIV+ men and 54% of HIV-
men reported self-perceived body fat changes in the abdomen (Table 1).
Physical and Mental HR-QoL among the HIV+ Men: Effect of Time
and Self-Perceived Body Fat Changes
At the baseline visit, PCS was not significantly different between men with or
without facial fat changes (Table 2). In contrast, men who self-perceived
moderate/severe body fat changes in the legs and abdomen had lower PCS
compared to men with no self-perceived body fat changes at these sites. At the
follow-up visit, men with any self-perceived body fat changes in the face, legs, or
abdomen had significantly lower PCS than those without self-perceived body fat
Figure 2. CONSORT diagram of study participant enrollment for HIV+ and HIV- participants. HAART, highly active antiretroviral therapy; HR-QoL,
health related quality of life.
doi:10.1371/journal.pone.0114166.g002
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changes (p,0.05). Participants who did not initially report self-perceived body fat
changes had stable PCS between the baseline and follow-up visits (Table 2). While
there were trends towards significantly lower PCS between baseline and follow-up
Table 1. Participant Characteristics at Baseline Visit (5 +/21 years after Highly Active Antiretroviral Therapy [HAART] initiation) and Follow-up Visit (median
7.5 years later).
Characteristics HIV+ (N5270) HIV- (N5247)
Baseline Follow-up Baseline Follow-up
Age, years 47 (43,52) 49 (45,54)
Calendar year 2001 (2001, 2002) 2009 (2008, 2009) 2001 (2001, 2001) 2009 (2008, 2009)
White 224 (83%) 212 (86%)
Body mass index, kg/m2 24.4 (22.6,26.9) 26.1 (24.0,29.4)
College graduate 186 (69%) 185 (75%)
Current smoker 48 (18%) 43 (17%)
Nadir CD4 cell count, cells/uL 303 (187,461)
Current CD4 cell count, cells/uL 544 (374,770) 557 (414,748)
% visits with HIV-1 RNA ,400 copies/mL 80 (40,100) 92 (60,100)
Stavudine use 117 (43%) 11 (4%)
Zidovudine use 96 (36%) 40 (15%)
Protease inhibitor use 180 (67%) 151 (56%)
Hepatitis C infection 17 (6%) 14 (5%) 3 (1%) 3 (1%)
Comorbidity score 1 (1,2) 1 (1,2) 1 (0,1) 1 (1,2)
Depression 61 (23%) 56 (21%) 41 (17%) 41 (17%)
Hypertension 44 (16%) 53 (20%) 38 (15%) 63 (26%)
Diabetes 27 (10%) 39 (14%) 9 (4%) 29 (12%)
Dyslipidemia 213 (79%) 219 (81%) 139 (56%) 190 (77%)
Kidney disease 5 (2%) 73 (27%) 0 10 (4%)
Liver disease 5 (2%) 4 (1%) 0 1 (0%)
Cancer within 1 year 3 (1%) 9 (3%) 2 (1%) 4 (2%)
Self-reported body fat change
Lipoatrophy of face
None 131 (49%) 229 (93%)
Mild 76 (28%) 13 (5%)
Moderate/severe 63 (23%) 3 (1%)
Lipoatrophy of legs
None 118 (44%) 226 (91%)
Mild 75 (28%) 15 (6%)
Moderate/severe 77 (29%) 4 (2%)
Lipohypertrophy abdomen (%)
None 101 (37%) 109 (44%)
Mild 88 (33%) 85 (34%)
Moderate/severe 81 (30%) 49 (20%)
Values presented as number (%) or median (25th, 75th percentile).
Co-morbidity score defined as the sum number of the following co-morbid conditions: 1) depression, 2) hypertension, 3) diabetes mellitus, 4) dyslipidemia, 5)
kidney Disease, 6) liver disease, 7) cancer within 1 year.
doi:10.1371/journal.pone.0114166.t001
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visits across all mild or moderate/severe self-perceived body fat change
assessments, only the self-perception of moderate/severe body fat changes in the
abdomen reached statistical significance (47.2 versus 44.9, p50.02). Over the
same time interval, the HIV- men showed a significant decrease in PCS (baseline:
54.1 [95% CI: 48.9, 59.4] versus follow-up 52.0 [95% CI: 46.7, 57.3], p,0.001).
MCS were similar by the severity of body fat changes at all three anatomic sites
in the HIV+ men at both the baseline and follow-up visits (Table 2). Men who
reported moderate/severe body fat changes in the abdomen tended to have higher
MCS at the follow-up visit compared to baseline (46.2 versus 48.7, p50.053).
Over the same time interval, the HIV- men showed a significant increase in MCS
(baseline: 51.8 [95% CI: 45.0, 58.6] versus follow-up 54.0 [95% CI: 47.1, 60.8];
p50.004).
Physical and Mental HR-QoL in HIV+ and HIV- Men: Effect of HIV
Serostatus, Time, Self-Perceived Body Fat Changes and
Comorbidity
The effect of HIV serostatus and time on PCS without consideration of the self-
perceived body fat changes was first examined (Table 3; Model 1). Overall, PCS
was 3.89 points (95% CI: 25.45, 22.33) lower in the HIV+ than the HIV- men.
Increasing age and time (follow-up versus baseline visit) were associated lower
with PCS, but there was no difference in the magnitude of the PCS decrease
between baseline and follow-up visits by HIV serostatus. Inclusion of the severity
of body fat change into the regression model decreased the effect estimates of HIV
serostatus in the models of face or leg fat changes (47% and 48% decreases
Table 2. Adjusted1 mean physical component summary (PCS) and mental component summary (MCS) scores on the Short Form-36 by self-reported
severity of body fat changes at baseline and follow-up visit among HIV+ men.
Body Fat Change Location/Severity PCS (Mean [95% CI]) MCS (Mean [95% CI])
Baseline Visit Follow-up Visit P value{ Baseline Visit Follow-up Visit P value{
Face
None 49.9 (46.1, 53.7) 49.5 (45.7, 53.3) 0.61 48.3 (43.7, 52.8) 49.0 (44.5, 53.5) 0.43
Mild 47.6 (43.6, 51.7) 45.8 (41.7, 49.8)* 0.07 45.7 (40.9, 50.6) 46.4 (41.5, 51.2) 0.62
Moderate/Severe 47.4 (43.1, 51.7) 45.4 (41.1, 49.6)* 0.07 47.9 (42.8, 53.1) 48.9 (43.8, 54.0) 0.50
Leg
None 50.1 (46.2, 53.9) 49.5 (45.7, 53.3) 0.48 47.6 (43.0, 52.2) 48.8 (44.2, 53.4) 0.23
Mild 48.0 (43.9, 52.0) 46.1 (42.1, 50.1)* 0.06 47.5 (42.7, 52.4) 47.3 (42.5, 52.1) 0.86
Moderate/Severe 47.1 (42.8, 51.3)* 45.7 (41.5, 49.8)* 0.17 47.4 (42.3, 52.5) 48.5 (43.4, 53.5) 0.42
Abdomen
None 50.5 (46.6, 54.4) 50.3 (46.4, 54.2) 0.78 47.0 (42.3, 51.7) 47.5 (42.8, 52.1) 0.64
Mild 48.4 (44.5, 52.4) 47.2 (43.3, 51.2)* 0.19 48.9 (44.1, 53.6) 48.5 (43.8, 53.3) 0.77
Moderate/Severe 47.2 (43.1, 51.3)* 44.9 (40.8, 48.9)* 0.02 46.2 (41.3, 51.1) 48.7 (43.8, 53.5) 0.05
1All models were adjusted for age, race (white vs other), education (college vs no college), HAART use at the time of the visit, co-morbidity score, and
proportion of previous post-HAART visits with plasma HIV-1 RNA (viral load) ,400 copies/ml.
95% CI: 95% Confidence Interval; { p value comparing baseline to follow-up; * p value ,0.05 compared within visit to category ‘‘none’’
doi:10.1371/journal.pone.0114166.t002
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respectively), but had minimal effect on self-perceived abdominal body fat
changes (7% decrease in the HIV serostatus effect estimate). PCS was significantly
lower with increasing severity of self-perceived body fat changes at the all three
sites (face, leg, and abdomen). The results for the HIV serostatus effect and the
self-perceived body fat change severity effect were similar when the comorbidity
score was added to the regression models (Table 3), although a higher
comorbidity score was associated with lower PCS in all models.
In the fully adjusted model, both higher baseline age and time were associated
with higher MCS, suggesting an improvement in mental HR-QoL with increasing
age (Table 3). There was no difference in MCS by HIV serostatus. Increasing
comorbidity burden was strongly associated with lower MCS in all models (all
p,0.001). Severity of body fat change was not associated with differences in MCS,
with the exception that mild facial body fat changes were associated with
significantly lower MCS compared to no facial fat changes (22.62 [95%CI:
24.98,20.25]; p,0.05).
Discussion
HR-QoL is a multidimensional concept that focuses on the effects of health status
on one’s self-perceived HR-QoL. Although the long-term consequences of HIV-
related body fat changes on metabolic and cardiovascular risk are medically well-
appreciated, ours is the first analysis reporting upon of the impact of self-
perceived body fat changes on the change in HR-QoL over a median of 7.5 years,
adjusted for both HIV serostatus and comorbidity score. We have demonstrated
that body fat changes of any severity or anatomic location were strongly associated
with physical components of HR-QoL, independent of the impact of HIV
serostatus and comorbid diseases. Although the impact of body fat changes on
PCS increased with severity, participants that perceived only minor changes were
not immune to these effects. A difference of 2–3 points in PCS score, which was
seen in persons with minor self-perceived body fat changes, is similar to the
decreases seen for each decade of advancing age across a normative population
[30]. Furthermore, the PCS observed in our group with moderate to severe self-
perceived body fat changes at follow-up was similar to the mean PCS in a
normative population at least a decade older (65–74 years of age). Importantly,
PSC have been consistently stronger predictors of mortality than MSC across
multiple cohorts of HIV- participants [31,32], thus our findings may have
significant clinical implications in terms of mortality risk among persons with
lipoatrophy or lipohypertrophy.
The greater decline in physical HR-QoL observed among HIV+ men with self-
perceived body fat changes also suggests that these men are at an increased risk for
decline in physical function with aging compared to HIV- men. This hypothesis is
supported by findings from prior cross-sectional studies demonstrating an
association between body fat changes and a frailty-type phenotype [33], and a
separate longitudinal study that found lipoatrophy, lipohypertrophy, or both were
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predictive of a decline in grip strength [34]. The impact of body fat changes on
physical function is likely multifactorial: lipoatrophy may serve as a marker for
use of prior, more toxic ART associated with mitochondrial damage and impaired
exercise tolerance [35,36]. Lipoatrophy may be associated with a higher resting
energy expenditure [37] and result in greater levels of fatigue. Furthermore,
impaired skeletal muscle glucose uptake in lipoatrophy and lipohypertrophy may
limit exercise duration and intensity [38]; heightened levels of inflammation that
have been associated with body fat changes may directly impair skeletal muscle
[39]; and the loss of lower extremity fat may be accompanied by a loss in lower
extremity muscle mass [40].
In contrast to our expected findings, the mental health components of HR-QoL
were preserved among HIV+ men with self-reported lipoatrophy or lipohyper-
trophy of any severity. Although many prior studies have reported an association
between mental health and body fat changes, our lack of significant findings here
may reflect the selectivity of the domains of mental health assessed in the different
study questionnaires. Many prior studies explored specific domains of sexual
function, body image, or depressive symptomatology that are not assessed by the
more general mental health assessment of the SF-36 [15,18,19]. Of note, we also
failed to observe differences in SF-36 by the location of self-perceived body fat
changes, in contrast to prior studies that have shown a stronger association
between mood changes and facial lipoatrophy than with abdominal or leg fat
changes [18]. Significant improvements in SF-36 scores, Beck Depression Index
Scores, body image, and self-esteem have been demonstrated with treatment of
facial lipoatrophy among HIV+ persons [41,42].
Not only did we fail to see a detrimental effect of self-perceived body fat
changes on MSC, we observed significant overall improvement in the MSC scores
with advancing age among both HIV+ and HIV- men, similar to reported
observations across normative SF-36 values [30]. Prior studies have reported that
older adults with HIV may have fractured social networks due to HIV/AIDS
stigma or ageism [43], and that depression rates among HIV+ adults increase with
advancing age [44], leading to our expectation of a decline in MCS scores with
increasing age. We postulate that one possible explanation of our findings is that
the stigma of lipoatrophy and lipohypertrophy is reduced as the body fat changes
are attributed to aging rather than HIV infection. The loss of facial or leg fat and
gain in central fat mirror age-associated changes in body fat albeit often appearing
at earlier ages [45,46]. Furthermore, the increase in MSC may represent greater
resilience in our participants [47,48], including resolved internalized homophobia
[49], or that the potentially stigmatizing effects of lipoatrophy and lipohyper-
trophy are of little importance in the current ART era.
Our study has several limitations. First, the study population included only
men. HIV+ women may have different or more pronounced manifestations of
lipoatrophy and lipohypertrophy with differential effects on mental and physical
HR-QoL [3,14,19]. Second, we used a measure of self-reported body fat changes
rather than physician-diagnosed changes in body fat. Although self-reported body
fat changes correlate well with physician-diagnosed changes, self-reported changes
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are consistently more common and more severe than provider-diagnosed changes
and may be a more sensitive measure of subtle changes in body fat [2,15]. The
questionnaire that we used to assess self-perceived body fat changes was similar to
questionnaires used in other studies that featured an inclusive of a range of
responses to either an increase or decrease in body fat from none, mild, moderate,
to severe. For this study, we evaluated only the changes in face, legs, or abdomen,
and therefore may have missed effects of other self-perceived fat changes such as
dorsocervical fat pads or arm lipoatrophy. Lastly, although the MACS men were
diverse in terms of age, socioeconomic status, race/ethnicity and geographic
region, they may not be nationally representative of HIV+ or HIV- men.
The main strength of our study is the longitudinal data collection: all exposures
were ascertained consistently across the cohort over time for both HIV+ and HIV-
men. Due to the size of our study population, we were able to adjust for age, HIV
serostatus, and comorbidity score, ensuring that the analysis of HR-QoL changes
were not due to these common confounders of HR-QoL. We determined the
impact of body fat changes at three different anatomic sites, each of which could
have different effects on perceptions of health [15,18].
In summary, we found a strong association between self-perceived body fat
changes and declines in physical but not mental HR-QoL, independent of the
effects of chronologic age, calendar time, and comorbidity burden over 7.5 years.
Among HIV+ men, self-perceived body fat changes may be a marker of increased
risk for physical function decline with aging. Interventions to preserve physical
function with aging could be informed by investigating the interrelationship of
objective body fat changes, self-perception of body fat changes, and physical
function.
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